EPS for Anthem (ANTM) Expected At $3.27; Last Week Alnylam Pharmaceuticals, Inc. (ALNY) Coverage

July 17, 2017 - By Darrin Black

Among 19 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 11 have Buy rating, 0 Sell and 8 Hold. Therefore 58% are positive. Alnylam Pharmaceuticals had 46 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Wednesday, November 16 by Needham. As per Thursday, October 6, the company rating was downgraded by Barclays Capital. The firm has “Buy” rating given on Monday, June 12 by Chardan Capital Markets. JP Morgan downgraded it to “Neutral” rating and $115 target in Friday, August 7 report. Piper Jaffray maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Monday, August 31 with “Overweight” rating. As per Thursday, June 22, the company rating was reinitiated by Jefferies. Credit Suisse maintained the stock with “Buy” rating in Tuesday, July 11 report. JP Morgan upgraded the shares of ALNY in report on Friday, March 11 to “Overweight” rating. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Outperform” rating by FBR Capital on Tuesday, August 11. The rating was initiated by Jefferies with “Buy” on Friday, October 23. See Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) latest ratings:

11/07/2017 Broker: Cowen & Co Rating: Buy New Target: $100.0000 Maintain
11/07/2017 Broker: Credit Suisse Rating: Buy New Target: $96.0000 Maintain
10/07/2017 Broker: Needham Rating: Buy New Target: $98.0000 Maintain
07/07/2017 Broker: Chardan Capital Markets Rating: Buy Maintain
27/06/2017 Broker: Credit Suisse Rating: Buy New Target: $96.0000
26/06/2017 Broker: BMO Capital Markets Rating: Buy New Target: $105.0000 Maintain
26/06/2017 Broker: Cowen & Co Rating: Buy New Target: $100.0000 Maintain
26/06/2017 Broker: Needham Rating: Buy New Target: $98.0000 Maintain
26/06/2017 Broker: J.P. Morgan Rating: Hold
22/06/2017 Broker: Jefferies Rating: Buy New Target: $102.0000 Reinitiate

Analysts expect Anthem Inc (NYSE:ANTM) to report $3.27 EPS on July, 26 before the open.They anticipate $0.06 EPS change or 1.80% from last quarter’s $3.33 EPS. ANTM’s profit would be $866.58M giving it 14.72 P/E if the $3.27 EPS is correct. After having $4.68 EPS previously, Anthem Inc’s analysts see -30.13% EPS growth. The stock increased 0.01% or $0.02 on July 14, reaching $192.56. About shares traded. Anthem Inc (NYSE:ANTM) has risen 31.86% since July 17, 2016 and is uptrending. It has outperformed by 15.16% the S&P500.

Anthem, Inc. is a health benefits company. The company has market cap of $51.03 billion. The Firm operates through three divisions: Commercial and Specialty Business, Government Business and Other. It has a 18.66 P/E ratio. It offers a spectrum of network managed care plans to large and small employer, individual, Medicaid and Medicare markets.

Among 21 analysts covering Anthem Inc (NYSE:ANTM), 8 have Buy rating, 0 Sell and 13 Hold. Therefore 38% are positive. Anthem Inc had 41 analyst reports since July 27, 2015 according to SRatingsIntel. On Thursday, July 30 the stock rating was maintained by RBC Capital Markets with “Outperform”. Oppenheimer maintained it with “Outperform” rating and $171 target in Thursday, October 29 report. As per Thursday, January 28, the company rating was maintained by RBC Capital Markets. RBC Capital Markets maintained the shares of ANTM in report on Thursday, October 29 with “Outperform” rating. The rating was maintained by Deutsche Bank with “Hold” on Thursday, July 13. Leerink Swann maintained it with “Outperform” rating and $195 target in Monday, April 4 report. RBC Capital Markets maintained the stock with “Buy” rating in Wednesday, July 5 report. Bernstein initiated the shares of ANTM in report on Thursday, June 16 with “Outperform” rating. The company was upgraded on Monday, July 27 by Sterne Agee CRT. The firm has “Buy” rating given on Friday, April 8 by Cleveland.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $7.09 billion. The Firm is engaged in the discovery, development and commercialization of ribonucleic acid interference (RNAi) therapeutics. It currently has negative earnings. The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Investors sentiment decreased to 0.77 in 2016 Q4. Its down 0.25, from 1.02 in 2016Q3. It is negative, as 64 investors sold Alnylam Pharmaceuticals, Inc. shares while 65 reduced holdings. 35 funds opened positions while 64 raised stakes. 78.05 million shares or 3.80% more from 75.19 million shares in 2016Q3 were reported. Hemenway Tru Communications Ltd Company invested 0.16% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Fmr Ltd Liability reported 0.06% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Cowen Gru has 11,200 shares. 40,510 were reported by Dekabank Deutsche Girozentrale. Macquarie Gru Limited reported 17,755 shares stake. The Switzerland-based Bb Biotech Ag has invested 1.65% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Tci Wealth Advsr has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 9 shares. Credit Suisse Ag owns 178,667 shares. Great West Life Assurance Co Can has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Teacher Retirement Of Texas invested in 6,239 shares or 0% of the stock. Van Eck Associate holds 126,692 shares or 0.02% of its portfolio. Fic Capital Inc has 3.25% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 172,242 shares. Goldman Sachs Grp Inc stated it has 914,437 shares or 0.01% of all its holdings. 12 West Capital Limited Partnership holds 700,000 shares. Bridger Lc reported 1.87% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Since January 18, 2017, it had 2 buys, and 5 insider sales for $16.24 million activity. 297,501 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares with value of $21.38 million were bought by Sanofi. $751,502 worth of stock was bought by KEATING LAURIE on Tuesday, May 30. Mason Michael sold 9,375 shares worth $656,250. Another trade for 43,750 shares valued at $2.84M was made by Vaishnaw Akshay on Monday, May 15. $995,125 worth of stock was sold by SHARP PHILIP A on Wednesday, February 1.

The stock decreased 1.54% or $1.23 on July 14, reaching $78.74. About shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since July 17, 2016 and is uptrending. It has outperformed by 16.84% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: